Cantor Fitzgerald analyst Louise Chen reinstated coverage of Humanigen with a Neutral rating and $0.15 price target. Humanigen has has shifted its focus to the development of lenzilumab in chronic myelomonocytic leukemia, in acute graft versus host disease, and in combination with CAR-T therapies, and while there is still a lot of value to be unlocked for shares, Chen remains on the sidelines until earnings visibility improves, the analyst tells investors in a research note.
Published first on TheFly